CRISPR Therapeutics Post Positive Results From Its CTX 100TM Trial, Targets Approval in Q1, 2022
(CRISPR Therapeutics) CRISPR Therapeutics posted positive updated results from the ongoing Phase 1 CARBON trial evaluating the safety and efficiency of CTX110TM, its allogeneic CAR-T cell therapy targeting CD19+ B-cell…